Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell Design Labs

- PMLiVE

Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

- PMLiVE

Gilead launches European hep C awareness drive

Aims to highlight significance of cure through patient storytelling initiative

Gilead Sciences

Gilead’s hepatitis C sales start to slide – the question is how quickly?

CEO anticipates eventual “equilibrium” through shift toward treatment of less severely ill patients

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

- PMLiVE

Juno cleared to restart CAR-T trial after deaths

Study attributes fatalities to pre-conditioning therapy, not the cancer immunotherapy

- PMLiVE

Gilead’s Zydelig passes EMA safety review

Risk of ‘serious infections’ outweighed by cancer drug’s benefits

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links